Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report

BACKGROUND: The programmed cell death 1 (PD-1) inhibitor pembrolizumab is a promising agent for treatment of several different malignancies, but as with all immunotherapy there is a potential risk of immune-related adverse events. Adrenocorticotropic hormone (ACTH) deficiency and hypophysitis have b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Diabetes Endocrinol
Main Authors: Tanaka, Sho, Kushimoto, Masaru, Nishizawa, Tsukasa, Takubo, Masahiro, Mitsuke, Kazutaka, Ikeda, Jin, Fujishiro, Midori, Ogawa, Katsuhiko, Tsujino, Ichiro, Suzuki, Yutaka, Abe, Masanori
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6945618/
https://ncbi.nlm.nih.gov/pubmed/31921440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40842-019-0092-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados